When should atropine and pralidoxime be discontinued in a patient being treated for organophosphate poisoning?

When to Discontinue Atropine and Pralidoxime in Organophosphate Poisoning

Discontinue atropine when full atropinization is achieved and maintained for at least 48-72 hours without recurrence of cholinergic symptoms, while pralidoxime should be continued as long as circulating poison is present or signs of toxicity recur—which may require treatment for up to 10 days depending on the organophosphate involved.

Atropine Discontinuation Criteria

Primary Endpoint: Full Atropinization

Stop atropine when the patient demonstrates:

• Inhibition of secretions (dry mouth, reduced bronchorrhea)
• Absence of muscarinic symptoms (no bradycardia, bronchospasm, or excessive salivation)
• Maintained for 48-72 hours minimum without symptom recurrence 1, 2

Critical Monitoring Period

• Keep patients under observation for at least 48-72 hours after apparent recovery 2
• Some degree of atropinization should be maintained throughout this period 2
• Watch for relapse, especially with ingested organophosphates where continuing absorption from the lower bowel can constitute new exposure 2

Warning Signs Requiring Continued Therapy

Do NOT stop atropine if:

• Cholinergic symptoms recur (bronchorrhea, miosis, bradycardia)
• Blood cholinesterase activity remains depressed 2
• Evidence of ongoing poison absorption exists

Pralidoxime Discontinuation Criteria

Extended Duration Required

Pralidoxime requires significantly longer treatment than traditionally practiced:

• Continue for up to 10 days if circulating poison is expected 3
• The traditional 1-2 day discontinuation is inadequate and can lead to relapse 4

Specific Discontinuation Triggers

Stop pralidoxime when ALL of the following are met:

1. No recurrence of nicotinic symptoms (muscle weakness, fasciculations, respiratory muscle paralysis)
2. Acetylcholinesterase activity normalized or aging is complete (making further reactivation impossible) 5
3. No circulating organophosphate detected (based on clinical assessment and time since exposure)
4. Minimum 48-72 hours have passed, but extend to 10 days if needed 3

Organophosphate-Specific Considerations

Dimethyl compounds (e.g., monocrotophos):

• Rapid "aging" of acetylcholinesterase-organophosphate bond
• Oximes may become ineffective within hours
• Consider earlier discontinuation if acetylcholinesterase is completely aged 5

Diethyl compounds (e.g., parathion, chlorpyrifos):

• Slow aging process
• Patients may benefit from prolonged oxime therapy even if no improvement seen initially 3
• Continue for several days as reactivation becomes possible when poison concentration drops 3, 4

Clinical Decision Algorithm

Step 1: Assess Acetylcholinesterase Status

• Measure acetylcholinesterase activity and reactivatability 5
• If completely aged: oxime therapy unlikely beneficial
• If reactivatable: continue pralidoxime

Step 2: Monitor for Symptom Recurrence

• "Titrate" the patient with pralidoxime as long as signs of poisoning recur 2
• Repeated doses every 3-8 hours may be needed with ingested organophosphates 2

Step 3: Evaluate Route of Exposure

Ingestion: Longer treatment duration required (up to 10 days) due to:

• Slow absorption from gastrointestinal tract
• Redistribution from lipid stores
• Metabolic activation of certain compounds 6

Dermal/inhalation: May require shorter duration if decontamination was thorough

Step 4: Clinical Improvement Assessment

Monitor for:

• Resolution of muscle weakness and fasciculations
• Stable respiratory function without support
• Normalized vital signs
• Absence of breakthrough symptoms

Common Pitfalls to Avoid

1. Premature discontinuation of pralidoxime at 24-48 hours: This outdated practice can lead to relapse of nicotinic symptoms 4. Case reports demonstrate successful management with 6-day continuous infusions 6.

2. Stopping therapy when anticholinergic symptoms appear: This may indicate atropine excess, not organophosphate resolution. Reduce atropine but continue monitoring 6.

3. Failing to recognize ongoing absorption: Fatal relapses occur after initial improvement when poison continues absorbing from the gut 2.

4. Not considering the specific organophosphate: Dimethyl vs. diethyl compounds have vastly different aging rates affecting oxime efficacy 3.

Maintenance Dosing Until Discontinuation

Pralidoxime: Maintain therapeutic levels (13.8 mg/L for pralidoxime chloride or 3.6 mg/L for obidoxime) via continuous infusion 3:

• Pralidoxime chloride: 0.5 g/hour infusion
• Obidoxime chloride: 0.75 g/24 hours

Atropine: Adjust to maintain mild atropinization without toxicity (avoid delirium, hyperthermia, muscle twitching) 2

The evidence strongly supports prolonged monitoring and treatment duration rather than arbitrary time-based discontinuation 3, 4, 7. Clinical status, acetylcholinesterase activity, and organophosphate type should guide the decision, not calendar days alone.